Precision BioSciences Set for Breakout with Key Gene Editing Trials
AI Prediction of Precision BioSciences, Inc. (DTIL)
Precision BioSciences, a clinical stage gene editing company, is positioned for potential share price appreciation with upcoming clinical catalysts. The company's focus on gene-editing therapies for high unmet needs, specifically its PBGENE-HBV and PBGENE-DMD programs, offers significant upside potential.
Precision BioSciences is actively developing its proprietary ARCUS genome editing platform to create in vivo gene editing therapies targeting diseases with high unmet needs. Key programs include PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. Both programs are approaching significant clinical milestones, with expected data readouts that could serve as major catalysts for the stock. The company's strategic focus on these diseases, combined with a robust clinical development pipeline and a strong cash position to support operations through 2028, positions Precision BioSciences as a compelling investment in the biotech sector. These factors are expected to significantly influence the company's stock price in the near term.
DTIL Report Information
Prediction Date2026-03-23
Close @ Prediction$6.52
Mkt Cap180m
IPO DateN/a
AI-derived Information
Recent News for DTIL
- May 27, 2:30 am — Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 (Business Wire)
- May 26, 3:00 am — Die Leo International Precision Health AG baut eine durchgängig vernetzte Präzisionsgesundheitsplattform auf, die den gesamten Behandlungs- und Versorgungspfad von Patienten abdeckt (GlobeNewswire RSS)
- May 26, 3:00 am — Leo International Precision Health AG builds a Synchronised, End-to-End Precision Healthcare Engine Across the Entire Patient Journey (GlobeNewswire RSS)
- May 22, 4:00 pm — Leo International Precision Health AG: Mr Leo Wang, Kauf (GlobeNewswire RSS)
- May 22, 4:00 pm — Leo International Precision Health AG: Mr Leo Wang, Acquisition (GlobeNewswire RSS)
- May 22, 4:00 pm — Leo International Precision Health AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung (GlobeNewswire RSS)
- May 22, 4:00 pm — Leo International Precision Health AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (GlobeNewswire RSS)
- May 22, 2:04 pm — Leo International Precision Health AG beschließt Barkapitalerhöhung unter Ausschluss des Bezugsrechts (GlobeNewswire RSS)
- May 22, 2:04 pm — Leo International Precision Health AG approves cash capital increase excluding subscription rights (GlobeNewswire RSS)
- May 21, 8:47 am — FDA Veteran Paz Vellanki, MD, PhD, Joins Precision for Medicine, Forming a Trio of Former Regulatory Leaders (PRNewswire RSS)
- May 21, 8:00 am — FLYTE ACTIVATES HIGH-FREQUENCY MEMORIAL DAY WEEKEND FLIGHT NETWORK TO CAPTURE SURGING NORTHEAST DEMAND (GlobeNewswire RSS)
- May 21, 7:01 am — Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026 (Business Wire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest